Michel Vounatsos's Insider Trades & SAST Disclosures
Michel Vounatsos's most recent trade in Zai Lab Limited - ADR was a trade of 21,253 American Depositary Shares done . Disclosure was reported to the exchange on June 18, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Michel Vounatsos.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Zai Lab Limited - ADR | Michel Vounatsos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 21,253 | 39,585 (0%) | 0% | 0 | American Depositary Shares | |
| Revvity Inc. | Michel Vounatsos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 1,218 | 9,285 (0%) | 0% | 0 | Common Stock | |
| Revvity Inc. | Michel Vounatsos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 977 | 8,067 (0%) | 0% | 0 | Common Stock | |
| Revvity Inc. | Michel Vounatsos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 955 | 7,090 (0%) | 0% | 0 | Common Stock | |
| Revvity Inc. | Michel Vounatsos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 783 | 6,135 (0%) | 0% | 0 | Common Stock | |
| Revvity Inc. | Michel Vounatsos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2022 | 744 | 5,352 (0%) | 0% | 0 | Common Stock | |
| Revvity Inc. | Michel Vounatsos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2022 | 610 | 4,608 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Michel Vounatsos | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 18 Feb 2022 | 8,909 | 30,210 | - | - | Restricted Stock Unit | |
| Biogen Inc | Michel Vounatsos | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 6,191 | 39,119 | - | - | Restricted Stock Unit | |
| Biogen Inc | Michel Vounatsos | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 6,191 | 70,007 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Michel Vounatsos | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 209.79 per share. | 18 Feb 2022 | 2,746 | 67,261 (0%) | 0% | 209.8 | 576,083 | Common Stock |
| Biogen Inc | Michel Vounatsos | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 12 Feb 2022 | 8,205 | 0 | - | - | Restricted Stock Unit | |
| Biogen Inc | Michel Vounatsos | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 12 Feb 2022 | 8,163 | 12,564 | - | - | Restricted Stock Unit | |
| Biogen Inc | Michel Vounatsos | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 214.59 per share. | 12 Feb 2022 | 4,699 | 63,816 (0%) | 0% | 214.6 | 1,008,358 | Common Stock |
| Biogen Inc | Michel Vounatsos | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2022 | 4,395 | 70,465 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Michel Vounatsos | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2022 | 4,395 | 20,727 | - | - | Restricted Stock Unit | |
| Biogen Inc | Michel Vounatsos | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2022 | 4,321 | 8,205 | - | - | Restricted Stock Unit | |
| Biogen Inc | Michel Vounatsos | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2022 | 4,321 | 67,987 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Michel Vounatsos | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 214.59 per share. | 12 Feb 2022 | 1,950 | 68,515 (0%) | 0% | 214.6 | 418,451 | Common Stock |
| Biogen Inc | Michel Vounatsos | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 214.59 per share. | 12 Feb 2022 | 1,917 | 66,070 (0%) | 0% | 214.6 | 411,369 | Common Stock |
| Biogen Inc | Michel Vounatsos | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 28,405 | 28,405 | - | - | Restricted Stock Unit | |
| Biogen Inc | Michel Vounatsos | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2022 | 10,594 | 63,666 (0%) | 0% | 0 | Common Stock | |
| Revvity Inc. | Michel Vounatsos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2021 | 709 | 3,998 (0%) | 0% | 0 | Common Stock | |
| Revvity Inc. | Michel Vounatsos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2021 | 604 | 3,289 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Michel Vounatsos | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2021 | 45,310 | 45,310 | - | - | Restricted Stock Unit | |
| Biogen Inc | Michel Vounatsos | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 12 Feb 2021 | 7,263 | 12,526 | - | - | Restricted Stock Unit | |
| Biogen Inc | Michel Vounatsos | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 278.03 per share. | 12 Feb 2021 | 7,248 | 43,905 (0%) | 0% | 278.0 | 2,015,161 | Common Stock |
| Biogen Inc | Michel Vounatsos | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 12 Feb 2021 | 7,221 | 25,122 | - | - | Restricted Stock Unit | |
| Biogen Inc | Michel Vounatsos | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 12 Feb 2021 | 6,419 | 0 | - | - | Restricted Stock Unit | |
| Biogen Inc | Michel Vounatsos | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2021 | 5,693 | 6,419 | - | - | Restricted Stock Unit | |
| Biogen Inc | Michel Vounatsos | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2021 | 5,693 | 49,598 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Michel Vounatsos | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2021 | 5,337 | 32,343 | - | - | Restricted Stock Unit | |
| Biogen Inc | Michel Vounatsos | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2021 | 5,337 | 60,194 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Michel Vounatsos | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2021 | 5,259 | 19,789 | - | - | Restricted Stock Unit | |
| Biogen Inc | Michel Vounatsos | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2021 | 5,259 | 54,857 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Michel Vounatsos | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 278.03 per share. | 12 Feb 2021 | 2,525 | 57,669 (0%) | 0% | 278.0 | 702,026 | Common Stock |
| Biogen Inc | Michel Vounatsos | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 278.03 per share. | 12 Feb 2021 | 2,367 | 52,969 (0%) | 0% | 278.0 | 658,097 | Common Stock |
| Biogen Inc | Michel Vounatsos | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 278.03 per share. | 12 Feb 2021 | 2,333 | 55,336 (0%) | 0% | 278.0 | 648,644 | Common Stock |
| Biogen Inc | Michel Vounatsos | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2021 | 16,343 | 51,153 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Michel Vounatsos | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 241.31 per share. | 30 Nov 2020 | 3,100 | 34,810 (0%) | 0% | 241.3 | 748,047 | Common Stock |
| Revvity Inc. | Michel Vounatsos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2020 | 1,081 | 2,685 (0%) | 0% | 0 | Common Stock | |
| Revvity Inc. | Michel Vounatsos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2020 | 922 | 1,360 (0%) | 0% | 0 | Common Stock | |
| Revvity Inc. | Michel Vounatsos | Director | Grant, award, or other acquisition of securities at price $ 92.20 per share. | 08 May 2020 | 244 | 1,604 (0%) | 0% | 92.2 | 22,497 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges